Macquarie Healthcare Fund Class C (DLHCX)
Fund Assets | 783.96M |
Expense Ratio | 1.96% |
Min. Investment | $1,000 |
Turnover | n/a |
Dividend (ttm) | 3.26 |
Dividend Yield | 15.79% |
Dividend Growth | 149.05% |
Payout Frequency | Annual |
Ex-Dividend Date | Dec 3, 2024 |
Previous Close | 20.55 |
YTD Return | -1.86% |
1-Year Return | -0.63% |
5-Year Return | 27.65% |
52-Week Low | n/a |
52-Week High | n/a |
Beta (5Y) | n/a |
Holdings | 110 |
Inception Date | Jan 28, 2010 |
About DLHCX
DLHCX was founded on 2010-01-28. The Fund's investment strategy focuses on Health/Biotech with 1.98% total expense ratio. The minimum amount to invest in Delaware Group Equity Funds IV: Delaware Healthcare Fund; Class C Shares is $1,000 on a standard taxable account. Delaware Group Equity Funds IV: Delaware Healthcare Fund; Class C Shares seeks maximum long-term capital growth through capital appreciation. Normally, the Fund will invest at least 80% of its assets in the equity securities of healthcare companies, meaning companies that develop, produce or distribute products or services (the "80% policy").
Performance
DLHCX had a total return of -0.63% in the past year, including dividends. Since the fund's inception, the average annual return has been 11.43%.
Top 10 Holdings
47.42% of assetsName | Symbol | Weight |
---|---|---|
Eli Lilly and Company | LLY | 9.50% |
Boston Scientific Corporation | BSX | 5.35% |
UnitedHealth Group Incorporated | UNH | 4.90% |
Regeneron Pharmaceuticals, Inc. | REGN | 4.46% |
Merck & Co., Inc. | MRK | 4.17% |
Pfizer Inc. | PFE | 4.11% |
Chugai Pharmaceutical Co., Ltd. | 4519 | 3.96% |
AbbVie Inc. | ABBV | 3.69% |
Amgen Inc. | AMGN | 3.66% |
Roche Holding AG | ROG | 3.62% |
Dividend History
Ex-Dividend | Amount | Pay Date |
---|---|---|
Dec 3, 2024 | $3.26278 | Dec 4, 2024 |
Dec 4, 2023 | $1.31011 | Dec 5, 2023 |
Dec 2, 2022 | $2.274 | Dec 5, 2022 |
Dec 3, 2021 | $1.476 | Dec 6, 2021 |
Dec 4, 2020 | $1.496 | Dec 7, 2020 |
Dec 5, 2019 | $2.015 | Dec 6, 2019 |